Pharmaceuticals

Insilico Medicine's AI-powered drug ISM8969, a brain-penetrant inhibitor, has been cleared by the FDA for clinical trials in Parkinson's disease.

With strong Q1 momentum, Standex faces a complex market. Its upcoming Q2 results will offer key insights into global manufacturing and corporate strategy.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

Acrivon Therapeutics to unveil pivotal data showing high response rates for its targeted drug ACR-368 in an aggressive endometrial cancer subtype.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

A single patient with a debilitating eye pain condition gains access to an investigational therapy, offering hope where no approved treatments exist.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

Frost & Sullivan recognizes Verana Health as the top innovator in real-world evidence, a move solidifying its market dominance after a key oncology merger.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

A new partnership embeds programmatic ads into electronic health records, promising hyper-targeted marketing but raising questions about clinical disruption.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

A new global consortium aims to break the antibiotic R&D logjam, using open science and AI to combat the growing superbug crisis threatening millions.

Simulations Plus reveals its new AI-driven ecosystem, aiming to solve pharma's biggest R&D hurdles with a focus on regulatory trust and integration.

A major benefits group is pushing Congress to pass key healthcare reforms that could lower drug prices and hospital bills before a critical Jan. 30 deadline.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.